H.R. 4385
Referred to CommitteeResponsibility in Drug Advertising Act of 2017
Introduced 11/14/2017•115th Congress•House
Latest Action
Referred to the Subcommittee on Health.
11/17/2017 • House
Summary
Responsibility in Drug Advertising Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.Introduced in House • 11/14/2017
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Drug safety, medical device, and laboratory regulationMarketing and advertisingPrescription drugs
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (1)
Sponsor
R[
No cosponsors yet
Cosponsors may be added as the bill moves through Congress
Bill Journey
Originated in the House
Introduced
November 14, 2017
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Introduced in House11/14/2017